Former Senior Vice President and Chief Commercial Officer · LEXICON PHARMACEUTICALS, INC. (LXRX)

Thomas Garner

FY2024 is the first fiscal year CompBrief holds for Thomas Garner as a named executive officer of LEXICON PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,987,425

Salary $471,032Stock awards $488,330

4th of 9 named executive officers at Lexicon Pharmaceuticals by FY2024 total.

9 named officers on file for LEXICON PHARMACEUTICALS, FY2024

Thomas Garner’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • LXRX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how LEXICON PHARMACEUTICALS’s whole pay program stands against its peers

  • LEXICON PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LXRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2025 (DEF 14A).

Free

Get Thomas Garner’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Thomas Garner compensation by year

LEXICON PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as LEXICON PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$471,032
Bonus$0
Stock awards$488,330
Option awards$400,387
Non-equity incentive$0
Pension and deferred compensation$0
All other$627,676
Total$1,987,425

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LEXICON PHARMACEUTICALS, INC. DEF 14A filed April 22, 2025, accession 0001062822-25-000023, and prior-year filings. Open the filing on EDGAR.

How this page was built: the LEXICON PHARMACEUTICALS, INC. filed document, accession 0001062822-25-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2025.

LEXICON PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Lonnel CoatsFormer Chief Executive Officer and Director$3,512,773
Michael ExtonChief Executive Officer and Director$2,835,589
Jeffrey WadeFormer President and Chief Financial Officer$2,564,274
Thomas Garner · this pageFormer Senior Vice President and Chief Commercial Officer$1,987,425
Craig GranowitzSenior Vice President and Chief Medical Officer$1,588,383
Brian CrumSenior Vice President and General Counsel$1,430,607
Alan MainExecutive Vice President, Innovation and Chemical Sciences$1,396,523
Wendy McDermottSenior Vice President, Human Resources$1,111,711
Kristen AlexanderVice President, Finance and Accounting$613,245

The full LEXICON PHARMACEUTICALS compensation record

free company brief

This page is one person within LEXICON PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the LEXICON PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LEXICON PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Garner's compensation dossier · One-time report. No refunds.